Blincyto improves overall survival in B-cell precursor acute lymphoblastic leukaemia
Amgen has announced new data from a prespecified interim analysis of the Phase III TOWER study, in which Blincyto (blinatumomab) demonstrated an almost two-times increase in median overall survival (OS) compared to standard of care (SOC) in patients with B-cell precursor acute lymphoblastic leukaemia.
Click on this link for more information.
